The DOI matches its Crossref record; 44 of the 45 references it cites were found in a registry or an index.
PD-1 is a novel regulator of human B-cell activation
Abstract
The outcome of the adaptive immune response is determined by the integration of both positive and negative signals, respectively, induced upon the triggering of co-signaling receptors. One of them, programmed cell death 1 (PDCD1/PD-1) has largely been shown to be involved in the negative regulation of T-cell activation. However, PD-1 is also expressed on human B cells, and its role(s) in the process of human B-cell activation remains uncertain thus far. In this study, we describe the expression of PD-1 on the major human B-cells subsets isolated from peripheral blood and lymph nodes. We showed that PD-1 was expressed on naive B cells, was differentially expressed on peripheral IgM memory as compared with memory B cells and was lost on germinal center B cells. Expression of PD-1 ligands (PD-Ls) was induced by TLR9 activation. Finally, we showed that PD-1 was recruited to the B-cell receptor upon triggering. We determined that during TLR9 activation, blockade of PD-1/PD-Ls pathways indeed increased B-cell activation, proliferation and the production of inflammatory cytokines. Altogether, our results show, that, as reported in T cells, PD-1/PD-Ls complexes acted as inhibitors of the B-cell activation cascade and highlight the importance of devising future therapies able to modulate lymphocyte activation through the targeting of the PD-1/PD-Ls pathways.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Since other cell types (such as dendritic cells and B cells) can also be influenced by PD-1 signaling, inhibition of the PD-1/PD-L1 pathway may also have T cell-independent effects, whose impact on immune responses during checkpoint inhibitor therapy remain to be elucidated (36, 58).”
From Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations (2018) · cites this paper as [36]
Citations
Cites
Freeman, G. J., Long, A. J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L. J., Malenkovich, N., Okazaki, T., Byrne, M. C., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.7.1027 · Cited by 5,294
Ishida, Y., Agata, Y., Shibahara, K., & Honjo, T. (1992) · The EMBO Journal · doi:10.1002/j.1460-2075.1992.tb05481.x · Cited by 3,259
PD-L2 is a second ligand for PD-1 and inhibits T cell activation
Latchman, Y., Wood, C. R., Chernova, T., Chaudhary, D., Borde, M., Chernova, I., Iwai, Y., Long, A. J., Brown, J. A., Nunes, R., et al. (2001) · Nature Immunology · doi:10.1038/85330 · Cited by 2,955
Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4
Waterhouse, P., Penninger, J. M., Timms, E., Wakeham, A., Shahinian, A., Lee, K. P., Thompson, C. B., Griesser, H., & Mak, T. W. (1995) · Science · doi:10.1126/science.270.5238.985 · Cited by 2,766
Points of control in inflammation
Nathan, C. (2002) · Nature · doi:10.1038/nature01320 · Cited by 2,738
Dong, H., Zhu, G., Tamada, K., & Chen, L. (1999) · Nature Medicine · doi:10.1038/70932 · Cited by 2,496
Greenwald, R. J., Freeman, G. J., & Sharpe, A. H. (2005) · Annual Review of Immunology · doi:10.1146/annurev.immunol.23.021704.115611 · Cited by 2,318
Butte, M. J., Keir, M. E., Phamduy, T. B., Sharpe, A. H., & Freeman, G. J. (2007) · Immunity · doi:10.1016/j.immuni.2007.05.016 · Cited by 1,785
Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes
Agata, Y., Kawasaki, A., Nishimura, H., Ishida, Y., Tsubat, T., Yagita, H., & Honjo, T. (1996) · International Immunology · doi:10.1093/intimm/8.5.765 · Cited by 1,589
Hamanishi, J., Mandai, M., Iwasaki, M., Okazaki, T., Tanaka, Y., Yamaguchi, K., Higuchi, T., Yagi, H., Takakura, K., Minato, N., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0611533104 · Cited by 1,378
Cited by
Sorted by citations
Items 201–300 of 365
Sørensen, A. L., Bjørn, M. E., Riley, C. H., Holmström, M. O., Andersen, M. H., Svane, I. M., Mikkelsen, S. U., Skov, V., Kjær, L., Hasselbalch, H. C., et al. (2019) · European Journal Of Haematology · doi:10.1111/ejh.13292 · Cited by 16
Okurut, S., Meya, D. B., Bwanga, F., Olobo, J. O., Eller, M. A., Cham-Jallow, F., Bohjanen, P. R., Pratap, H., Palmer, B. E., Hullsiek, K. H., et al. (2019) · Infection and Immunity · doi:10.1128/iai.00779-19 · Cited by 16
Cutaneous Adverse Events of Anti-PD-1 Therapy and BRAF Inhibitors
Gnanendran, S., Turner, L. M., Miller, J. A., Hwang, S. J. E., & Miller, A. C. (2020) · Current Treatment Options in Oncology · doi:10.1007/s11864-020-0721-7 · Cited by 16
Immune Cells in Head-and-Neck Tumor Microenvironments
Jumaniyazova, E. D., Lokhonina, А. V., Dzhalilova, D. S., Kosyreva, A. M., & Fatkhudinov, T. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12091521 · Cited by 15
Mechanism underlying the immune checkpoint inhibitor-induced hyper-progressive state of cancer
Ding, P., Wen, L., Tong, F., Zhang, R., Huang, Y., & Dong, X. (2022) · Cancer Drug Resistance · doi:10.20517/cdr.2021.104 · Cited by 15
Aristolochic Acid and Immunotherapy for Urothelial Carcinoma: Directions for unmet Needs
Yang, H., Yang, C., Wu, C., Wang, L.-J., & Lu, K. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20133162 · Cited by 15
Serum PD-1 Is Elevated after Pembrolizumab Treatment but Has No Predictive Value
Music, M., Iafolla, M. A. J., Ren, A. H., Soosaipillai, A. R., Prassas, I., & Diamandis, E. P. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-0132 · Cited by 15
Medical Treatment of Lung Cancer: Can Immune Cells Predict the Response? A Systematic Review
Rochigneux, P., Garcia, A. J., Chanez, B., Madroszyk, A., Olive, D., & Garon, E. B. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01036 · Cited by 17
Gui, S., O’Neill, W. Q., Teknos, T. N., & Pan, Q. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001259 · Cited by 14
Fallon, E. A., Chung, C., Heffernan, D. S., Chen, Y., Paepe, M. E. D., & Ayala, A. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.634529 · Cited by 14
Johnson, J., Kim, S., Sam, P. K., Asokan, R., Cari, E. L., Bales, E. S., Luu, T., Perez, L., Kallen, A. N., Nel‐Themaat, L., et al. (2022) · American Journal of Reproductive Immunology · doi:10.1111/aji.13649 · Cited by 15
Cell Identity and Spatial Distribution of PD‐1/PD‐L1 Blockade Responders
Li, X., Liu, Y., Gui, J., Gan, L., & Xue, J. (2024) · Advanced Science · doi:10.1002/advs.202400702 · Cited by 17
Pembrolizumab-induced Pure Red Cell Aplasia Successfully Treated with Intravenous Immunoglobulin
Isoda, A., Miyazawa, Y., Tahara, K., Mihara, M., Saito, A., Matsumoto, M., & Sawamura, M. (2020) · Internal Medicine · doi:10.2169/internalmedicine.4467-20 · Cited by 14
Czaja, A. J. (2019) · Autoimmunity · doi:10.1080/08916934.2019.1641200 · Cited by 15
Zhu, Q., Li, Y., Zhang, L., Wang, M., Chen, Z., Shi, J., Li, J., Li, B., Li, Z., Wang, Y., et al. (2020) · Clinical Rheumatology · doi:10.1007/s10067-020-05220-2 · Cited by 14
See, J.-X., Samudi, C., Abdulla, M. A., Vadivelu, J., & Shankar, E. M. (2017) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0005702 · Cited by 17
Hait, S. H., Vargas‐Inchaustegui, D. A., Musich, T., Mohanram, V., Tuero, I., Venzon, D. J., Bear, J., Rosati, M., Vaccari, M., Franchini, G., et al. (2018) · Journal of Virology · doi:10.1128/jvi.01687-18 · Cited by 13
Gutiérrez, C., López‐Abente, J., Pérez-Fernández, V. A., Prieto-Sánchez, A., Correa‐Rocha, R., Moreno, S., Muñoz‐Fernández, M. Á., & Pion, M. (2019) · PLoS ONE · doi:10.1371/journal.pone.0213744 · Cited by 13
Prospective role of PD-1/PD-L1 immune checkpoint inhibitors in GI cancer
AmeliMojarad, M., AmeliMojarad, M., & Cui, X. (2023) · Pathology - Research and Practice · doi:10.1016/j.prp.2023.154338 · Cited by 13
A Case of Organizing Pneumonia (OP) Associated with Pembrolizumab
Fragkou, P. C., Souli, M., Theochari, M., Kontopoulou, C., Loukides, S., & Koumarianou, A. (2016) · Drug Target Insights · doi:10.33393/dti.2016.1420 · Cited by 13
Zheng, S., Wang, H., Mu, J., Liu, X., Jin, X., Li, Z., Jiang, J., & Yang, M. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-07346-w · Cited by 12
Zhang, Y., Huang, W., Chen, D., Zhao, Y., Sun, F., Wang, Z., & Lou, G. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.823082 · Cited by 12
Ma, K., Chen, S., Chen, X., Zhao, X., & Yang, J. (2022) · Journal of Molecular Neuroscience · doi:10.1007/s12031-022-02060-4 · Cited by 12
Novel anticancer therapy in BCG unresponsive non-muscle-invasive bladder cancer
Moussa, M. A., Papatsoris, A., Dellis, A., Chakra, M. A., & Saad, W. (2020) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2020.1822743 · Cited by 12
Inverse Vaccination for Autoimmune Diseases: Insights into the Role of B Lymphocytes
Zouali, M. (2025) · Cells · doi:10.3390/cells14141085 · Cited by 11
Willsmore, Z. N., Booth, L. H., Patel, A. J., Meo, A. D., Prassas, I., Chauhan, J., Wu, Y., Fitzpartick, A., Stoker, K., Kapiris, M., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-011682 · Cited by 11
PD‐1 mediates decidual γδ T cells cytotoxicity during recurrent pregnancy loss
Guo, R., Jiang, S., Zhang, J., Yang, Q., Gao, L., Xia, W., Tong, L., Feng, P., Xu, Y., Zhang, T., et al. (2022) · American Journal of Reproductive Immunology · doi:10.1111/aji.13562 · Cited by 11
Cogbill, C. H., Swerdlow, S. H., & Gibson, S. E. (2014) · American Journal of Clinical Pathology · doi:10.1309/ajcpwf77vognovzu · Cited by 11
Treating tumors with immune checkpoint inhibitors: Rationale and limitations
Seidel, J. A., Otsuka, A., & Kabashima, K. (2017) · Trends in Immunotherapy · doi:10.24294/ti.v1.i1.20 · Cited by 11
Investigational drugs with dual activity against HBV and HIV (Review)
Sun, S., Yang, Q., Sheng, Y., Fu, Y., Sun, C., & Deng, C. (2020) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2020.9467 · Cited by 10
Checkpoint Inhibitors and Induction of Celiac Disease-like Condition
Lerner, A., & Benzvi, C. (2022) · Biomedicines · doi:10.3390/biomedicines10030609 · Cited by 10
Dynamic changes in B cell subpopulations in response to triple-negative breast cancer development
Gonçalves, I. V., Pinheiro-Rosa, N., Torres, L., Oliveira, M. D. A., Guimarães, G. R., Leite, C. D. S., Ortega, J. M., Lopes, M. T. P., Faria, A. M. C., Boroni, M., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-60243-y · Cited by 11
Antibodies against endogenous retroviruses
Chisca, M., Larouche, J., Xing, Q., & Kassiotis, G. (2024) · Immunological Reviews · doi:10.1111/imr.13378 · Cited by 9
Yu, F., Zhu, Y., Li, S., Hao, L., Li, N., Ye, F., Jiang, Z. D., & Hu, X. (2024) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2024.1488527 · Cited by 11
Global FDR control across multiple RNAseq experiments
Liou, L., Hornburg, M., & Robertson, D. S. (2022) · Bioinformatics · doi:10.1093/bioinformatics/btac718 · Cited by 9
Facing SARS-CoV-2 Outbreak in Immunotherapy Era
Citarella, F., Russano, M., Pantano, F., Dell’Aquila, E., Vincenzi, B., Tonini, G., & Santini, D. (2020) · Future Oncology · doi:10.2217/fon-2020-0340 · Cited by 9
Saad, F. T., & Hınçal, E. (2018) · The European Physical Journal Plus · doi:10.1140/epjp/i2018-12092-0 · Cited by 9
Mihăilescu, M., Brockstein, B., Desai, N., & Waldinger, J. B. (2020) · Current Problems in Cancer Case Reports · doi:10.1016/j.cpccr.2020.100031 · Cited by 9
B cell dysfunction in chronic hepatitis B virus infection
Ma, L., Sun, X., Kong, X., & Gao, Y. (2020) · Liver Research · doi:10.1016/j.livres.2020.09.004 · Cited by 9
Hadfield, M. J., Merkin, R. D., Rouhani, S. J., & Reynolds, K. L. (2025) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2025.101625 · Cited by 8
Rajah, D. A., Tan, H. S., & Farghadani, R. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.115339 · Cited by 9
Frelau, A., Jali, E., Campillo‐Gimenez, B., Pracht, M., Porneuf, M., Dinulescu, M., Edeline, J., Boussemart, L., & Lesimple, T. (2021) · Melanoma Research · doi:10.1097/cmr.0000000000000739 · Cited by 8
A Case of Acquired Factor V Inhibitor Following Nivolumab Administration
Kida, W., Nakaya, M., Ito, A., Kozai, Y., & Bingo, M. (2022) · Cureus · doi:10.7759/cureus.21670 · Cited by 8
Roy, S., Gupta, A. K., Banerjee, M., Das, P. K., & Ukil, A. (2023) · Cellular Immunology · doi:10.1016/j.cellimm.2023.104758 · Cited by 8
Xie, Q., Hu, C., & Luo, C. (2023) · Journal of Cancer · doi:10.7150/jca.88101 · Cited by 9
Comprehensive multiplexed autoantibody profiling of patients with advanced urothelial cancer
Ravi, P. K., Freeman, D. A., Thomas, J. V., Ravi, A., Mantia, C. M., McGregor, B. A., Berchuck, J. E., Epstein, I. B., Budde, P. I., Abhari, B. A., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-008215 · Cited by 8
Determining clinically relevant features in cytometry data using persistent homology
Mukherjee, S., Wethington, D., Dey, T. K., & Das, J. (2022) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1009931 · Cited by 8
Pejovic, T. B., Abate, P.-V., Ma, H., Thiessen, J., Corless, C. L., Peterson, A., Allard‐Chamard, H., & Labrie, M. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.903806 · Cited by 10
Zhang, L., Wang, I., Solban, N., Cristescu, R., Zeng, G., & Long, B. J. (2020) · Molecular Medicine Reports · doi:10.3892/mmr.2020.11169 · Cited by 7
Thyroid dysfunction (TD) induced by PD-1/PD-L1 inhibitors in advanced lung cancer
Wang, Y., Yang, X., Ma, J., Chen, S., Gong, P., & Dai, P. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e27077 · Cited by 7
Ram, R., Amit, O., Perry, C., Herishanu, Y., Avivi, I. M., Sarid, N., Apel, A., Preis, M., Aviv, A., Shapira, S., et al. (2024) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2024.09.024 · Cited by 6
PD-1 is conserved from sharks to humans: new insights into PD-1, PD-L1, PD-L2, and SHP-2 evolution
Kondo, R., Kondo, K., Nabeshima, K., Nishikimi, A., Ishida, Y., Shigeoka, T., & Dijkstra, J. M. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1573492 · Cited by 6
Spatial and phenotypic plasticity of B cells in remodeling the tumor microenvironment
Gao, Y., Peng, Y., Chen, Y., Zeng, S., Shen, H., Martin, A., Cai, C., & Han, Y. (2026) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-014745 · Cited by 6
Salby, S. B., Persson, G., Pedersen, N. H., Turan, G., Kimmerslev, L., Finne, K. F., Weisdorf, I., Lebech, M., & Hviid, T. V. F. (2025) · Journal of Reproductive Immunology · doi:10.1016/j.jri.2025.104426 · Cited by 6
Refractory Nivolumab-Induced Myasthenia Gravis Treated With Abatacept
Khokher, W., Bhuta, S., Kesireddy, N., Abuhelwa, Z., Mhanna, M., Iftikhar, S., Horen, N. G., & Assaly, R. (2021) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000001405 · Cited by 6
Song, B., Wang, K., Na, S., Yao, J., Fattah, F. J., Martin, A. L., von Itzstein, M. S., Yang, D. M., Liu, J., Xue, Y., et al. (2025) · Nature Cancer · doi:10.1038/s43018-025-01001-5 · Cited by 5
Żukowska, P., Ciepiela, K., Kudrymska, A., Kiełbowski, K., & Becht, R. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13144236 · Cited by 5
Qian, S., Xu, J., Zhao, S., Yang, P., & Yang, C. (2021) · Clinical & Experimental Immunology · doi:10.1093/cei/uxab003 · Cited by 5
Mechanism and Management of Checkpoint Inhibitor-Related Toxicities in Genitourinary Cancers
Li, H., Sahu, K. K., & Maughan, B. L. (2022) · Cancers · doi:10.3390/cancers14102460 · Cited by 6
Immunotherapy in Advanced Non-Small Cell Lung Cancers: Current Status and Updates
Suraya, R., TACHIHARA, M. Y., Nagano, T., Nishimura, Y., & Kobayashi, K. (2022) · Cancer Management and Research · doi:10.2147/cmar.s366738 · Cited by 6
Neuromuscular complications associated with cancer immunotherapy
Xiong, G., Lomen‐Hoerth, C., Richman, D. P., & Li, T. (2025) · Journal of the National Cancer Center · doi:10.1016/j.jncc.2025.05.004 · Cited by 5
Fritzsch, A., Leucht, K., Röber, N., Conrad, K., Rothe, R., Wehner, R., Schumacher, U., Esteban, E., Barthélémy, P., Schmidinger, M., et al. (2025) · ESMO Open · doi:10.1016/j.esmoop.2025.105575 · Cited by 4
Peripheral blood RNA biomarkers can predict lesion severity in degenerative cervical myelopathy
Zheng, Z., Chen, J., Xu, J., Jiang, B., Dai, Y., Li, Y., Dai, Y., & Wang, B. (2024) · Neural Regeneration Research · doi:10.4103/nrr.nrr-d-23-01069 · Cited by 5
B Cell Subsets and Immune Checkpoint Expression in Patients with Chronic Lymphocytic Leukemia
Ntsethe, A., Mkhwanazi, Z. A., Dludla, P. V., & Nkambule, B. B. (2024) · Current Issues in Molecular Biology · doi:10.3390/cimb46030112 · Cited by 4
Yordanova, A., Ivanova, M. G., Tumangelova-Yuzeir, K. D., Angelov, A. K., Kyurkchiev, S., Belemezova, K., Kurteva, E. K., Kyurkchiev, D. S., & Ivanova‐Todorova, E. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252312515 · Cited by 4
Hanamura, I., Suzuki, S., Ota, A., Murakami, S., Satou, A., Takahara, T., Karnan, S., Lam, V. Q., Nakamura, A., Takasugi, S., et al. (2021) · Hemato · doi:10.3390/hemato2020023 · Cited by 4
Papadimitriou, M., Liakouli, Z., & PAPADIMITRIOU, C. A. (2021) · Journal of Cancer Metastasis and Treatment · doi:10.20517/2394-4722.2021.138 · Cited by 4
Таширева, Л. А., Popova, N. O., Kalinchuk, A. V., Goldberg, V. E., Kovalenko, E. I., Артамонова, Е. В., Manikhas, A., Ponomarenko, D. M., Levchenko, N. V., Ивановна, Р. Е., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.909505 · Cited by 4
Zhou, J., Huang, C., Zhu, H., & Chen, Z. (2022) · Infectious Microbes & Diseases · doi:10.1097/im9.0000000000000082 · Cited by 4
IFN-γ versus IL-17: A Battle During Cardiac Autoimmunity Evolution
Kurtenbach, E., & Martinez, C. G. (2017) · InTech eBooks · doi:10.5772/66986 · Cited by 3
Khaled, C., Kim, M., & Min, B. (2025) · Experimental & Molecular Medicine · doi:10.1038/s12276-025-01562-6 · Cited by 3
Aziz, I. N., Gajjar, R., Nandyal, S. R., Oredipe, O., QADDORAH, S., Amdetsion, G. Y., Valencia, J. G., & Tottleben, J. (2025) · European Heart Journal - Case Reports · doi:10.1093/ehjcr/ytaf593 · Cited by 3
The role of programmed cell death 1 in autoimmune diseases: mechanisms and therapeutic implications
Liu, Z.-Y., Hu, Z.-P., Lao, H.-L., Chen, L., Wen, Y., Liang, Y.-Q., Zhang, C., Wu, J., & Hou, X.-L. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1707084 · Cited by 2
Nie, H., Chen, T., He, K., Liang, C., Guo, W., & Shi, X. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.680327 · Cited by 3
Κούτρας, Ν., Morfos, V., Konnaris, K., Kouvela, A., Shaukat, A., Stathopoulos, C., Stamatopoulou, V., & Nika, K. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1224520 · Cited by 3
Li, T.-D., Wang, P., Sun, G., Zou, Y.-L., Cheng, Y.-F., Wang, H., Lu, Y., Shi, J.-X., Wang, K.-Y., Zhang, Q., et al. (2023) · Journal of Proteome Research · doi:10.1021/acs.jproteome.3c00579 · Cited by 3
Idel, C., Fleckner, J., Plötze‐Martin, K., Werner, L., Rades, D., Theodoraki, M., Hofmann, L., Huber, D., Leichtle, A., Hoffmann, T. K., et al. (2024) · BMC Cancer · doi:10.1186/s12885-024-12177-x · Cited by 3
Emerging roles of checkpoint molecules on B cells
Asashima, H., Akao, S., & Matsumoto, I. (2025) · Immunological Medicine · doi:10.1080/25785826.2025.2454045 · Cited by 3
Wargantiwar, S., Bhattacharya, S., & Kanugo, A. (2025) · Current Medicinal Chemistry · doi:10.2174/0109298673337745241123054840 · Cited by 3
Hu, X., Rodday, A. M., Gurinovich, A., Pan, S. S., Salei, Y. V., Lin, J. H., Byrne, M. M., Cao, Y., Pai, L. H., & Parsons, S. K. (2025) · Immunotherapy · doi:10.1080/1750743x.2025.2488728 · Cited by 3
Transitional and CD21− PD-1+ B cells are associated with remission in early rheumatoid arthritis
McGrath, S., Sundbeck, B., Thorarinsdottir, K., Jonsson, C. A., Camponeschi, A., Agelii, M. L., Ekwall, A. H., Hetland, M. L., Østergaard, M., Uhlig, T., et al. (2025) · BMC Rheumatology · doi:10.1186/s41927-025-00487-x · Cited by 3
Cao, G., Memida, T., Huang, S., Abdolahinia, E. D., Ruiz, S., Hassantash, S., Ari, J. C., Shindo, S., Lin, J., Kawai, T., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26115332 · Cited by 4
Zhang, Q., Zhang, Y., Chen, Y., Liu, X., Li, J., Liu, F., Wang, J., Zhao, Y., Zhang, K., Sang, L., et al. (2025) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2025.111610 · Cited by 3
Mini‐review: Immunology in ovarian cancer
Taki, M. (2023) · Journal of obstetrics and gynaecology research · doi:10.1111/jog.15730 · Cited by 3
Unveiling the immune dynamics of Neisseria persistent oral colonization
Alles, M., Gunasena, M. G. B., Zia, T., D’Mello, A., Bhattarai, S. S., Mulhern, W., Terry, L., Scherger, T., Wijeratne, S., Singh, S., et al. (2024) · Infection and Immunity · doi:10.1128/iai.00048-24 · Cited by 3
B lymphocyte-mediated humoral immunity in the pathogenesis of chronic hepatitis B infection
Pan, J., Yao, T., Cheng, H., Zhu, Y., & Wang, Y. (2020) · Liver Research · doi:10.1016/j.livres.2020.07.001 · Cited by 3
Eleftheriadis, T., Pissas, G., Liakopoulos, V., & Stefanidis, I. (2021) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000365 · Cited by 3
Lepone, L. M., Donahue, R. N., Grenga, I., Metenou, S., Richards, J., Heery, C. R., Madan, R. A., Gulley, J. L., & Schlom, J. (2016) · Journal of Circulating Biomarkers · doi:10.33393/jcb.2016.2071 · Cited by 2
Hervet, C., Perrin, A., Renson, P., Deblanc, C., Muñoz, M., Meurens, F., Argilaguet, J. M., Simon, G., Bourry, O., Maisonnasse, P., et al. (2025) · Molecular Immunology · doi:10.1016/j.molimm.2025.10.010 · Cited by 2
Wang, W., Lu, J., Yan, Y., Wen, K., Guo, G., Zhou, Z., & Xiao, Z. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1696376 · Cited by 2
Ohkuma, R., Onishi, N., Watanabe, M., Jin, J., Ariizumi, H., Shimokawa, M., Ikeda, G., Ishiguro, T., Suzuki, R., Tsurui, T., et al. (2026) · Scientific Reports · doi:10.1038/s41598-026-46923-x · Cited by 2
A Review of Therapeutic Antibodies in Breast Cancer
Eini, M., Zainodini, N., Montazeri, H., Mirzabeigi, P., & Tarighi, P. (2021) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.18433/jpps31864 · Cited by 4
Identification of Immune-Related Genes as Biomarkers for Uremia
Lyu, D., He, G., Zhou, K., Xu, J., Zeng, H., Li, T., & Tang, N. (2023) · International Journal of General Medicine · doi:10.2147/ijgm.s435732 · Cited by 2
Ntsethe, A., Dludla, P. V., & Nkambule, B. B. (2025) · Biomedicines · doi:10.3390/biomedicines13030741 · Cited by 2
Multifaceted function of B cells in tumorigenesis
Kang, N., Duan, Q., Min, X., Li, T., Li, Y., Gao, J., & Liu, W. (2025) · Frontiers of Medicine · doi:10.1007/s11684-025-1127-5 · Cited by 2
Sammons, S. L., McNamara, M. A., Salama, A. K. S., & Crawford, J. (2018) · Springer eBooks · doi:10.1007/978-3-319-70253-7_12 · Cited by 2
Mostafa, M. A. O., Elseidy, S. A., El-Metwally, R., Mahmoud, A. A., Abdelhay, A., & Imran, F. S. (2024) · Clinical Immunology Communications · doi:10.1016/j.clicom.2024.04.001 · Cited by 2
Badmazhapova, D. S., Galtseva, I. V., Zvonkov, E. E., Davydova, Y. O., Михайлович, К. Н., Chernova, N. G., Gabeeva, N. G., Моисеева, Т. Н., Kovrigina, A. M., Николаевна, Д. В., et al. (2018) · Oncohematology · doi:10.17650/1818-8346-2018-13-1-103-114 · Cited by 2
Lu, Y. Z., Zhu, Q., Li, Y., Wang, Q., Jiang, C., Li, Z., Wang, H., Wang, Y., Zhang, W., Wang, Y., et al. (2020) · doi:10.21203/rs.2.17942/v2 · Cited by 2
Cmai: Predicting Antigen-Antibody Interactions from Massive Sequencing DataPreprint
Song, B., Wang, K., Na, S., Yao, J., Fattah, F. J., von Itzstein, M. S., Yang, D. M., Liu, J., Xue, Y., Liang, C., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.06.27.601035 · Cited by 2
Metadata
- Authors
- Thibult, M.-L., Mamessier, E., Gertner-Dardenne, J., Pastor, S., Just-Landi, S., Xerri, L., Chetaille, B., & Olive, D.
- Affiliations
- Inserm (FR)
- Centre de Recherche en Cancérologie de Marseille (FR)
- Venue
- International Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2012-10-18
- Volume
- 25
- Issue
- 2
- Pages
- 129-137
- ISSN
- 0953-8178 (ISSN-L)
- 1460-2377
- OpenAlex
- W2131640081
- Cited by
- 365
- References
- 45
- Citations by year
- 2026: 16 · 2025: 28 · 2024: 38 · 2023: 25 · 2022: 44 · 2021: 43 · 2020: 47 · 2019: 38 · 2018: 27 · 2017: 20 · 2016: 19 · 2015: 8 · 2014: 8 · 2013: 4
- FWCI
- 2.79
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- International Immunology (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immune Response and Inflammation
- Keywords
- PD-1, PD-L1, PD-L2, B cell activation, B cell receptor signaling, TLR9, naive B cells, memory B cells, germinal center B cells, B cell proliferation, inflammatory cytokines
- MeSH terms
- B-Lymphocytes, Humans, Lymphocyte Activation, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
